1 / 20

Radioligand Therapy Market

The global radioligand therapy market was valued at $9,754.9 million in 2020 and is expected to reach $16,658.4 million by 2031, witnessing a CAGR of 4.67% during the forecast period 2021-2031.<br><br>

bisreports
Télécharger la présentation

Radioligand Therapy Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Radioligand Therapy Market - A Global and Regional Analysis Table of Content Attribution: https://pixabay.com/photos/tire-rim-car-mechanic-114259/ Focus on Indication, Product, Biomarker, and Region Radioligand Therapy Market Analysis and Forecast: 2021-2031 March 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Copyright © 2022 BIS Research Inc. Radioligand Therapy Market All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary .......................................................................... 19 1. Research Methodology .............................................................. 25 1.1 Radioligand Therapy: Research Methodology .............................................. 25 1.2 Primary Data Sources ..................................................................................... 26 1.3 Secondary Data Sources ................................................................................ 26 1.4 Market Estimation Model ................................................................................. 27 1.5 Criteria for Company Profiling ........................................................................ 29 2.Radioligand Therapy Market ...................................................... 30 2.1 Product Definition ............................................................................................ 31 2.1.1Inclusion and Exclusion ............................................................................. 31 2.2 Market Scope ................................................................................................... 31 2.2.1Scope of the Study ...................................................................................... 31 2.2.2Key Questions Answered in the Report .................................................... 32 2.3 Market Overview .............................................................................................. 33 2.3.1Market Definition ......................................................................................... 33 2.3.2Emerging Applications of Radioligand Therapy ....................................... 33 2.3.2.1 Neuroendocrine Neoplasms .................................................................................. 34 2.3.2.2 Prostate Cancer ..................................................................................................... 35 2.3.2.3 Non-Cancerous Condition ..................................................................................... 35 2.3.3Market Footprint and Growth Potential ..................................................... 36 2.3.4COVID-19 Impact on Global Radioligand Therapy Market ....................... 36 2.3.4.1 Impact on Radioligand Therapy ............................................................................. 36 Radioligand Therapy Market 2.3.4.2 Clinical Trial Disruptions and Resumptions ........................................................... 37 3.Industry Analysis ....................................................................... 38 3.1 Overview ........................................................................................................... 39 3.2 Challenges in Radioligand Therapy Regulatory Approval Pathway ........... 39 3 All rights reserved at BIS Research Inc.

  4. 3.3 Regulatory Scenario of Radioligand Therapy ............................................... 39 3.4 Legal Requirements and Frameworks in the U.S. ......................................... 41 3.4.1Clinical Trial Authorization ......................................................................... 41 3.4.2Marketing Authorization ............................................................................. 41 3.4.3U.S. FDA Guidelines for NDA Submission ................................................ 42 3.4.4Post-Authorization Regulations ................................................................. 43 3.5 Legal Requirements and Frameworks in Europe .......................................... 44 3.5.1EMA Drug License Application Process ................................................... 45 3.5.2Centralized Procedure ................................................................................ 46 3.5.3Decentralized Procedure ............................................................................ 46 3.5.4Mutual-Recognition Procedure .................................................................. 46 3.5.5National Procedure ...................................................................................... 46 3.6 Legal Requirements and Frameworks in Asia-Pacific .................................. 46 3.6.1Legal Requirements and Frameworks in Japan ....................................... 46 4.Pipeline Analysis ........................................................................ 48 4.1 Radioligand Therapy Pipeline Analysis ......................................................... 49 4.2 Radioligand Therapy Clinical Trial Design .................................................... 51 4.2.1[Lu-177]-PNT2002 ........................................................................................ 51 4.2.1.1 Product Profile ....................................................................................................... 51 4.2.1.2 [Lu-177]-PNT2002 Phase III Study Design ........................................................... 52 4.2.1.3 [Lu-177]-PNT2002 Efficacy, Safety, and Tolerability (Phase II) ............................ 54 4.2.1.4 177Lu-PNT2002 Pharmacokinetics and Pharmacodynamics Profile (Phase I)..... 55 4.2.2CAM H2 ......................................................................................................... 55 4.2.2.1 Product Profile ....................................................................................................... 55 Radioligand Therapy Market 4.2.2.2 CAM H2 Preclinical Study Design ......................................................................... 56 4.2.2.3 CAM H2 Phase I/IIa Clinical Study Design ............................................................ 56 4.2.3[177Lu]-NeoB ............................................................................................... 57 4.2.3.1 Product Profile ....................................................................................................... 57 4.2.3.2 (177Lu)-NeoB Preclinical Studies .......................................................................... 57 4 All rights reserved at BIS Research Inc.

  5. 4.2.3.3 (177Lu)-NeoB Phase I/II Clinical Study Design ..................................................... 58 4.2.4PNT-2003 ...................................................................................................... 59 4.2.4.1 Product Profile ....................................................................................................... 59 4.2.4.2 PNT 2003 Ongoing Phase III Clinical Study Design .............................................. 59 4.2.5ITM-11 ........................................................................................................... 60 4.2.5.1 Product Profile ....................................................................................................... 60 4.2.5.2 ITM-11 Preclinical Proof-of-Concept Studies ........................................................ 61 4.2.5.3 ITM-11 Phase III Clinical Trial Design ................................................................... 61 4.2.6177.Lu FAP-2286 .......................................................................................... 62 4.2.6.1 Product Profile ....................................................................................................... 62 4.2.6.2 177.Lu FAP, 2286 Preclinical Study Summary ...................................................... 62 4.2.6.3 177Lu-FAP-2286 Phase I/IIa Clinical Study Design .............................................. 62 4.2.7FPI-1434 ........................................................................................................ 63 4.2.7.1 Product Profile ....................................................................................................... 63 4.2.7.2 FPI-1434 Preclinical Study Summary .................................................................... 63 4.2.7.3 FPI-1434 Phase I/IIa Clinical Study Design ........................................................... 63 4.2.8FPI-1966 ........................................................................................................ 64 4.2.8.1 Product Profile ....................................................................................................... 64 4.2.8.2 FPI-1966 Preclinical Study Summary .................................................................... 64 4.2.9177Lu-DOTA-rosopatamab ......................................................................... 65 4.2.9.1 Product Profile ....................................................................................................... 65 4.2.9.2 TLX591 (177Lu-DOTA-rosopatamab) Ongoing Phase III Clinical Study Design ................................................................................................................... 65 5.Market Dynamics ....................................................................... 67 Radioligand Therapy Market 5.1 Overview ........................................................................................................... 68 5.2 Impact Analysis ............................................................................................... 68 5.3 Market Drivers .................................................................................................. 69 5.3.1Radioligand Therapy Demand Inclined by Rising Prevalence of Cancer ................................................................................................. 69 5 All rights reserved at BIS Research Inc.

  6. 5.3.2Strategic Initiatives by Key Market Players ............................................... 70 5.3.3Rise in Clinical Research Activity .............................................................. 71 5.4 Market Restraints ............................................................................................. 71 5.4.1High Cost Associated with Treatment and Complex Reimbursement Processes ........................................................................................... 71 5.4.2Increased Competition from Generics ....................................................... 72 5.5 Market Opportunities ....................................................................................... 72 5.5.1Expanding Radiopharmaceutical Coverage .............................................. 72 5.5.2Role of Radioligand in Drug Discovery ..................................................... 73 6.Competitive Landscape ............................................................. 74 6.1 Overview ........................................................................................................... 75 6.2 Product Launch ............................................................................................... 75 6.3 Product Approvals ........................................................................................... 76 6.4 Synergistic Activities ...................................................................................... 77 6.5 Mergers and Acquisitions ............................................................................... 77 6.6 Market Share Analysis (by Company), 2020 .................................................. 78 7.Global Radioligand Therapy Market, Indication, $Million, 2020- 2031 .......................................................................................... 79 7.1 Overview ........................................................................................................... 80 7.2 Prostate Cancer ............................................................................................... 81 7.3 Neuroendocrine Tumor (NETs) ....................................................................... 82 7.4 Other ................................................................................................................. 83 8.Global Radioligand Therapy Market, Products, $Million, 2020- Radioligand Therapy Market 2031 .......................................................................................... 84 8.1 Overview ........................................................................................................... 85 8.2 Approved Products ......................................................................................... 85 8.2.1Lutathera ...................................................................................................... 86 8.2.2Zytiga ............................................................................................................ 87 6 All rights reserved at BIS Research Inc.

  7. 8.2.3Xtandi ........................................................................................................... 88 8.2.4Xofigo ........................................................................................................... 89 8.3 Potential Pipeline ............................................................................................. 90 9.Global Radioligand Therapy Market, Biomarker, $Million, 2020-2031 .................................................................................. 93 9.1 Overview ........................................................................................................... 94 9.2 Prostate-Specific Membrane Antigen ............................................................ 95 9.3 Ki 67 Expression and Grading ........................................................................ 96 9.4 Cytochrome P450 17A1 Inhibitor .................................................................... 97 10.Global Radioligand Therapy Market, Region, $Million, 2020- 2031 .......................................................................................... 99 10.1Overview ......................................................................................................... 100 10.2North America ................................................................................................ 103 10.2.1 U.S. ....................................................................................................... 105 10.2.2 Canada ................................................................................................. 106 10.3Europe ............................................................................................................ 108 10.3.1 Germany .............................................................................................. 109 10.3.2 France .................................................................................................. 110 10.3.3 U.K. ....................................................................................................... 111 10.3.4 Italy ....................................................................................................... 112 10.3.5 Spain .................................................................................................... 113 10.3.6 Rest-of-Europe .................................................................................... 114 10.4Asia-Pacific .................................................................................................... 115 10.4.1 Japan .................................................................................................... 117 Radioligand Therapy Market 10.4.2 South Korea ......................................................................................... 118 10.4.3 Australia ............................................................................................... 119 10.4.4 Rest-of-Asia-Pacific (RoAPAC) .......................................................... 120 10.5Rest-of-the-World (RoW) ............................................................................... 121 11. Markets - Competitive Benchmarking & Company Profiles ...... 122 7 All rights reserved at BIS Research Inc.

  8. 11.1Overview ......................................................................................................... 123 11.2Johnson & Johnson Services, Inc. .............................................................. 124 11.2.1 Company Overview ............................................................................. 124 11.2.2 Role of Johnson & Johnson Services, Inc. in the Global Radioligand Therapy Market ........................................................... 124 11.2.3 Product ASP (by Region) ................................................................... 125 11.2.4 Key Competitors of Company ............................................................ 125 11.2.5 Financials ............................................................................................ 126 11.2.6 Key Insights About the Financial Health of the Company ............... 128 11.2.7 SWOT Analysis .................................................................................... 129 11.3Pfizer Inc. ........................................................................................................ 130 11.3.1 Company Overview ............................................................................. 130 11.3.2 Role of Pfizer Inc. in the Global Radioligand Therapy Market......... 130 11.3.3 Product ASP (by Region) ................................................................... 130 11.3.4 Key Competitors of Company ............................................................ 131 11.3.5 Financials ............................................................................................ 132 11.3.6 Key Insights About Financial Health of the Company ..................... 133 11.3.7 Business Strategies ............................................................................ 133 11.3.7.1 Product Approval ............................................................................................. 133 11.3.8 SWOT Analysis .................................................................................... 134 11.4Amneal Pharmaceuticals LLC. ..................................................................... 135 11.4.1 Company Overview ............................................................................. 135 11.4.2 Role of Amneal Pharmaceuticals LLC. in the Global Radioligand Therapy Market ................................................................................. 135 11.4.3 Key Competitors of Company ............................................................ 135 Radioligand Therapy Market 11.4.4 Financials ............................................................................................ 136 11.4.5 Key Insights About Financial Health of the Company ..................... 137 11.4.6 Business Strategies ............................................................................ 138 11.4.6.1 Product Launch ................................................................................................ 138 11.4.7 SWOT Analysis .................................................................................... 138 11.5Novartis International AG .............................................................................. 139 8 All rights reserved at BIS Research Inc.

  9. 11.5.1 Company Overview ............................................................................. 139 11.5.2 Role of Novartis International AG in the Global Radioligand Therapy Market ................................................................................. 139 11.5.3 Product ASP (by Region) ................................................................... 139 11.5.4 Key Competitors of Company ............................................................ 140 11.5.5 Financials ............................................................................................ 141 11.5.6 Key Insights About Financial Health of the Company ..................... 142 11.5.7 Corporate Strategies ........................................................................... 143 11.5.7.1 Mergers and Acquisitions ................................................................................ 143 11.5.7.2 Synergistic Activities ........................................................................................ 143 11.5.7.3 Business Expansion and Funding ................................................................... 143 11.5.8 Business Strategies ............................................................................ 143 11.5.8.1 Product Launches and Approval ...................................................................... 144 11.5.9 SWOT Analysis .................................................................................... 145 11.6POINT Biopharma Global Inc ........................................................................ 146 11.6.1 Company Overview ............................................................................. 146 11.6.2 Role of POINT Biopharma Global Inc in the Global Radioligand Therapy Market ................................................................................. 146 11.6.3 Key Competitors of Company ............................................................ 146 11.6.4 Corporate Strategies ........................................................................... 147 11.6.5 SWOT Analysis .................................................................................... 148 11.7Fusion Pharma ............................................................................................... 149 11.7.1 Company Overview ............................................................................. 149 11.7.2 Role of Fusion Pharma in the Global Radioligand Therapy Market ............................................................................................... 149 11.7.3 Key Competitors of Company ............................................................ 149 Radioligand Therapy Market 11.7.4 Financials ............................................................................................ 150 11.7.5 Key Insights About the Financial Health of the Company ............... 151 11.7.6 Corporate Strategies ........................................................................... 151 11.7.6.1 Synergistic Activities ........................................................................................ 151 11.7.7 SWOT Analysis .................................................................................... 152 9 All rights reserved at BIS Research Inc.

  10. 11.8Clovis Oncology ............................................................................................ 153 11.8.1 Company Overview ............................................................................. 153 11.8.2 Role of Clovis Oncology in the Global Radioligand Therapy Market ............................................................................................... 153 11.8.3 Key Competitors of Company ............................................................ 153 11.8.4 Financials ............................................................................................ 154 11.8.5 Key Insights About the Financial Health of the Company ............... 155 11.8.6 Corporate Strategies ........................................................................... 156 11.8.6.1 Mergers and Acquisitions ................................................................................ 156 11.8.7 SWOT Analysis .................................................................................... 156 11.9Telix Pharmaceuticals ................................................................................... 157 11.9.1 Company Overview ............................................................................. 157 11.9.2 Role of Telix Pharmaceuticals in the Global Radioligand Therapy Market ................................................................................. 157 11.9.3 Key Competitors of Company ............................................................ 157 11.9.4 Financials ............................................................................................ 158 11.9.5 Key Insights About the Financial Health of the Company ............... 159 11.9.6 Corporate Strategies ........................................................................... 159 11.9.6.1 Mergers and Acquisitions ................................................................................ 159 11.9.6.2 Synergistic Activities ........................................................................................ 159 11.9.7 SWOT Analysis .................................................................................... 160 11.10Lantheus Holdings, Inc. (Progenics Pharmaceuticals) .............................. 161 11.10.1 Company Overview ............................................................................. 161 11.10.2 Role of Lantheus Holdings Inc., (Progenics Pharmaceuticals) in the Global Radioligand Therapy Market ......................................... 161 Radioligand Therapy Market 11.10.3 Key Competitors of Company ............................................................ 161 11.10.4 Financials ............................................................................................ 162 11.10.5 Key Insights About the Financial Health of the Company ............... 164 11.10.6 Corporate Strategies ........................................................................... 164 11.10.6.1 Mergers and Acquisitions ................................................................................ 164 11.10.7 SWOT Analysis .................................................................................... 165 10 All rights reserved at BIS Research Inc.

  11. 11.11Bayer AG ........................................................................................................ 166 11.11.1 Company Overview ............................................................................. 166 11.11.2 Role of Bayer AG in the Global Radioligand Therapy Market ......... 166 11.11.3 Product ASP (by Region) ................................................................... 166 11.11.4 Key Competitors of Company ............................................................ 166 11.11.5 Financials ............................................................................................ 167 11.11.6 Key Insights About the Financial Health of the Company ............... 168 11.11.7 Corporate Strategies ........................................................................... 169 11.11.7.1 Mergers and Acquisitions ................................................................................ 169 11.11.7.2 Product Approval ............................................................................................. 169 11.11.8 SWOT Analysis .................................................................................... 169 11.12Molecular Partners ........................................................................................ 170 11.12.1 Company Overview ............................................................................. 170 11.12.2 Role of Molecular Partners in the Global Radioligand Therapy Market ............................................................................................... 170 11.12.3 Key Competitors of Company ............................................................ 170 11.12.4 SWOT Analysis .................................................................................... 171 12.Emerging Company Profiles. .................................................... 172 12.1ITM Isotope Technologies Munich SE ......................................................... 172 12.1.1 Company Overview ............................................................................. 172 12.1.2 Role of ITM Isotope Technologies Munich SE in the Global Radioligand Therapy Market ........................................................... 172 12.1.3 Key Competitors of Company ............................................................ 172 12.1.4 SWOT Analysis .................................................................................... 173 12.2Curium Pharma .............................................................................................. 174 Radioligand Therapy Market 12.2.1 Company Overview ............................................................................. 174 12.2.2 Role of Curium Pharma. in the Global Radioligand Therapy Market ............................................................................................... 174 12.2.3 Key Competitors of Company ............................................................ 174 12.2.4 SWOT Analysis .................................................................................... 175 11 All rights reserved at BIS Research Inc.

  12. 12.3Precirix ........................................................................................................... 176 12.3.1 Company Overview ............................................................................. 176 12.3.2 Role of Precirix in the Global Radioligand Therapy Market ............ 176 12.3.3 Key Competitors of Company ............................................................ 176 12.3.4 SWOT Analysis .................................................................................... 177 12.4Radio Medix .................................................................................................... 178 12.4.1 Company Overview ............................................................................. 178 12.4.2 Role of Radio Medix in the Global Radioligand Therapy Market .... 178 12.4.3 Key Competitors of Company ............................................................ 178 12.4.4 SWOT Analysis .................................................................................... 179 Radioligand Therapy Market 12 All rights reserved at BIS Research Inc.

  13. List of Figures Figure 1:Global Cancer Burden, 2020 Figure 2:Impact Analysis of Market Drivers and Market Challenges on the Global Radioligand Therapy Market Figure 3:Revenue Contribution of Different Segments, 2020, 2029, and 2031 Figure 4:Revenue Contribution of Different Segments, 2020, 2021, and 2031 Figure 5:Revenue Contribution of Different Segments, 2020, 2021, and 2031 Figure 6:Global Radioligand Therapy Market (by Region), $Million, 2023-2031 Figure 7:Global Radioligand Therapy Methodology Figure 8:Primary Research Methodology Figure 9:Epidemiology-Based Approach Figure 10:Global Radioligand Therapy Market Segmentation Figure 11:Global Radioligand Therapy Market, $Million, 2020-2031 Figure 12:Clinical Trial Authorization for Radioligand Therapy in the U.S. Figure 13:Steps for Obtaining Marketing Authorization Figure 14:U.S. FDA Review Timeline Figure 15:EMA Review Timeline Figure 16:Radioligand Therapy Global Clinical Trials (by Phase), 2021 Figure 17:Radioligand Therapy Global Clinical Trials 2021 Figure 18:177Lu-PSMA-617 (RA101495) Mechanism of Action Figure 19:[Lu-177]-PNT2002 Phase III Clinical Trial Design for Metastatic Castration-Resistant Prostate Cancer Figure 20:177Lu-PNT2002 Phase II Clinical Trial Design for Metastatic Castration-Resistant Prostate Cancer Figure 21:177Lu-PNT2002 PK/PD Profile Results Figure 22:CAM H2 Phase I Portion Clinical Study Figure 23:Solid Tumors with Overexpression Figure 24:(177Lu)-NeoB Preclinical Studies Framework Figure 25:(177Lu)-NeoB Phase I Portion Clinical Study Figure 26:Phase III clinical Design for PNT-2003 Figure 27:Results from ITM-11 Phase III Clinical Trial Figure 28:177Lu-FAP-2286 I/IIa Portion Clinical Study Figure 29:FPI-1434 I/IIa Portion Clinical Study Figure 30:Phase III clinical Design for PNT-2003 Figure 31:Global Cancer Burden, 2020 Figure 32:Share of Key Developments, January 2018-February 2022 Figure 33:Share of Product Approvals (by Company), January 2018-November 2021 Figure 34:Share of Synergistic Activities (by Company), January 2018-February 2022 Figure 35:Share of Mergers and Acquisitions (by Company), January 2018-February 2022 Radioligand Therapy Market 13 All rights reserved at BIS Research Inc.

  14. Figure 36:Market Share Analysis of Global Radio Ligand Therapy Market (by Company), 2020 Figure 37:Revenue Contribution of Different Segments, 2020, 2039, and 2031 Figure 38:Global Radioligand Therapy Market (Prostate Cancer), $Million, 2020-2031 Figure 39:Global Radioligand Therapy Market (Neuroendocrine Tumors), $Million, 2025-2031 Figure 40:Global Radioligand Therapy Market (Others), $Million, 2029-2031 Figure 41:Global Radioligand Therapy Market Segmentation (by Product) Figure 42:Global Radioligand Therapy Market (Approved Products), $Million, 2020-2031 Figure 43:Global Radioligand Therapy Market (Lutathera), $Million, 2020-2031 Figure 44:Global Radioligand Therapy Market (Zytiga), $Million, 2020-2031 Figure 45:Global Radioligand Therapy Market (Xtandi), $Million, 2020-2031 Figure 46:Global Radioligand Therapy Market (Xofigo), $Million, 2020-2031 Figure 47:Global Radioligand Therapy Market (Potential Pipeline), $Million, 2024-2031 Figure 48:Global Radioligand Therapy Market (by Potential Pipeline Drugs (Phase 3)), $Million, 2024- 2031 Figure 49:Global Radioligand Therapy Market (by Potential Pipeline Drugs (Phase 2)), $Million, 2029- 2031 Figure 50:Global Radioligand Therapy Market (by Biomarker) Figure 51:Global Radioligand Therapy Market (by Biomarker), $Million, 2020 and 2031 Figure 52:Global Radioligand Therapy Market (Prostate-Specific Membrane Antigen), $Million, 2020- 2031 Figure 53:Global Radioligand Therapy Market (Ki 67 Expression and Grading), $Million, 2020-2031 Figure 54:Global Radioligand Therapy Market (Cytochrome P450 17A1 Inhibitor), $Million, 2020-2031 Figure 55:Global Radioligand Therapy Market Snapshot (by Region), $Million, 2020-2031 Figure 56:Global Radioligand Therapy Market (by Region), $Million, 2020-2031 Figure 57:North America Radioligand Therapy Market, $Million, 2020-2031 Figure 58:North America: Market Dynamics Figure 59:North America Radioligand Therapy Market (by Country), $Million, 2020-2031 Figure 60:U.S. Radioligand Therapy Market, $Million, 2020-2031 Figure 61:Canada Radioligand Therapy Market, $Million, 2020-2031 Figure 62:Europe Radioligand Therapy Market, $Million, 2020-2031 Figure 63:Europe: Market Dynamics Figure 64:Europe Radioligand Therapy Market (by Country), $Million, 2020-2031 Figure 65:Germany Radioligand Therapy Market, $Million, 2020-2031 Figure 66:France Radioligand Therapy Market, $Million, 2020-2031 Figure 67:U.K. Radioligand Therapy Market, $Million, 2020-2031 Figure 68:Italy Radioligand Therapy Market, $Million, 2020-2031 Figure 69:Spain Radioligand Therapy Market, $Million, 2020-2031 Figure 70:Rest-of Europe Radioligand Therapy Market, $Million, 2020-2031 Figure 71:Asia-Pacific Radioligand Therapy Market, $Million, 2020-2031 Figure 72:Asia-Pacific: Market Dynamics Figure 73:APAC Radioligand Therapy Market (by Country), $Million, 2020-2031 Radioligand Therapy Market 14 All rights reserved at BIS Research Inc.

  15. Figure 74:Japan Radioligand Therapy Market, $Million, 2020-2031 Figure 75:South Korea Radioligand Therapy Market, $Million, 2020-2031 Figure 76:Australia Radioligand Therapy Market, $Million, 2020-2031 Figure 77:RoAPAC Radioligand Therapy Market, $Million, 2020-2031 Figure 78:Rest-of-the-World (RoW) Radioligand Therapy Market, $Million, 2020-2031 Figure 79:Total Number of Companies Profiled Figure 80:Johnson & Johnson Services, Inc.: Product Portfolio Figure 81:Johnson & Johnson Services, Inc.: Overall Financials, $Million, 2018-2020 Figure 82:Johnson & Johnson Services, Inc.: Revenue (by Segment), $Million, 2018-2020 Figure 83:Johnson & Johnson Services, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 84:Johnson & Johnson Services, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 85:Johnson & Johnson Services, Inc.: SWOT Analysis Figure 86:Pfizer Inc.: Commercialized Therapy Figure 87:Pfizer Inc.: Overall Financials, $Million, 2018-2020 Figure 88:Pfizer Inc.: Revenue (by Region), $Million, 2018-2020 Figure 89:Pfizer Inc.: R&D Expenditure, $Million, 2018-2020 Figure 90:Pfizer Inc.: SWOT Analysis Figure 91:Amneal Pharmaceuticals LLC.: Commercialized Therapy Figure 92:Amneal Pharmaceuticals LLC.: Overall Financials, $Million, 2018-2020 Figure 93:Amneal Pharmaceuticals LLC.: Revenue (by Segment), $Million, 2018-2020 Figure 94:Amneal Pharmaceuticals LLC.: R&D Expenditure, $Million, 2018-2020 Figure 95:Amneal Pharmaceuticals.: SWOT Analysis Figure 96:Novartis International AG: Commercialized Therapy Figure 97:Novartis International AG: Pre-Clinical and Clinical Assets Figure 98:Novartis International AG: Overall Financials, $Million, 2018-2020 Figure 99:Novartis International AG: Revenue (by Segment), $Million, 2018-2020 Figure 100:Novartis International AG: Revenue (by Region), $Million, 2018-2020 Figure 101:Novartis International AG: R&D Expenditure, $Million, 2018-2020 Figure 102:Novartis International AG: SWOT Analysis Figure 103:POINT Biopharma Global Inc.: Pipeline Therapy Figure 104:POINT Biopharma Global Inc.: SWOT Analysis Figure 105:Fusion Pharma: Pipeline Portfolio Figure 106:Fusion Pharma: Overall Financials, $Million, 2019-2020 Figure 107:Fusion Pharma: R&D Expenditure, $Million, 2019-2020 Figure 108:Fusion Pharma: SWOT Analysis Figure 109:Clovis Oncology.: Pipeline Portfolio Figure 110:Clovis Oncology.: Overall Financials, $Million, 2018-2020 Figure 111:Clovis Oncology.: Revenue (by Region), $Million, 2019-2020 Figure 112:Clovis Oncology.: R&D Expenditure, $Million, 2018-2020 Figure 113:Clovis Oncology.: SWOT Analysis Radioligand Therapy Market 15 All rights reserved at BIS Research Inc.

  16. Figure 114:Telix Pharmaceuticals: Product Portfolio Figure 115:Telix Pharmaceuticals: Overall Financials, $Million, 2018-2020 Figure 116:Telix Pharmaceuticals: R&D Expenditure, $Million, 2018-2020 Figure 117:Telix Pharmaceuticals.: SWOT Analysis Figure 118:Lantheus Holdings Inc., (Progenics Pharmaceuticals): Pipeline Portfolio Figure 119:Lantheus Holdings Inc. (Progenics Pharmaceuticals): Overall Financials, $Million, 2018- 2020 Figure 120:Lantheus Holdings Inc. (Progenics Pharmaceuticals): Revenue (by Segment), $Million, 2019 and 2020 Figure 121:Lantheus Holdings Inc. (Progenics Pharmaceuticals): Revenue (by Region), $Million, 2018-2020 Figure 122:Lantheus Holdings Inc. (Progenics Pharmaceuticals): R&D Expenditure, $Million, 2018- 2020 Figure 123:Lantheus Holdings Inc. (Progenics Pharmaceuticals): SWOT Analysis Figure 124:Bayer AG.: Product Portfolio Figure 125:Bayer AG.: Overall Financials, $Million, 2018-2020 Figure 126:Bayer AG: Revenue (by Region), $Million, 2018-2020 Figure 127:Bayer AG.: R&D Expenditure, $Million, 2018-2020 Figure 128:Bayer AG.: SWOT Analysis Figure 129:Molecular Partners.: Product Portfolio Figure 130:Molecular Partners.: SWOT Analysis Figure 131:ITM Isotope Technologies Munich SE: Product Portfolio Figure 132:ITM Isotope Technologies Munich SE: SWOT Analysis Figure 133:Curium Pharma.: Product Portfolio Figure 134:Curium Pharma: SWOT Analysis Figure 135:Precirix: Product Portfolio Figure 136:Precirix: SWOT Analysis Figure 137:Radiomedix: Product Portfolio Figure 138:RadioMedix: SWOT Analysis Radioligand Therapy Market 16 All rights reserved at BIS Research Inc.

  17. List of Tables Table 1: Table 2: Table 3: Table 4: Table 5: Table 6: Table 7: Regulatory Scenario of Radioligand Therapy Emerging Radioligand Therapy Pipeline Likert Scale Impact Analysis of Market Drivers Impact Analysis of Market Restraints Lutathera ASP by Region Xtandi: Indications Radioligand Therapy Market 17 All rights reserved at BIS Research Inc.

  18. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More Radioligand Therapy Market Know More 18 All rights reserved at BIS Research Inc.

  19. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published, or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates, and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 Radioligand Therapy Market 19 All rights reserved at BIS Research Inc.

  20. BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Radioligand Therapy Market Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 20 www.bisresearch.com All rights reserved at BIS Research Inc.

More Related